Revolution Medicines, Inc. (RVMD)

Market Cap	11.09B
Revenue (ttm)	n/a
Net Income (ttm)	-812.06M
Shares Out	186.93M
EPS (ttm)	-4.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,396,043
Open	58.53
Previous Close	58.57
Day's Range	58.00 - 60.00
52-Week Range	29.17 - 62.40
Beta	0.99
Analysts	Strong Buy
Price Target	76.31 (+28.6%)
Earnings Date	Nov 5, 2025

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 534
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Summary

According to 16 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $76.31, which is an increase of 28.60% from the latest price.

Price Target

$76.31

(28.60% upside)

Analyst Consensus: Strong Buy